Health

Ticagrelor or Prasugrel in Patients with Acute Coronary Syndromes

Supported by a grant (FKZ 81X1600501) from the German Center for Cardiovascular Research and Deutsches Herzzentrum München.

Disclosure forms provided by the authors are available with the full text of this article at NEJM.org.

Dr. Schüpke reports receiving consulting fees from Bayer Vital and grant support from Else Kröner–Fresenius–Stiftung; Dr. Neumann, receiving lecture fees, paid to his institution, from Amgen, Daiichi Sankyo, Novartis, and Ferrer, lecture fees, paid to his institution, and consulting fees, paid to his institution, from AstraZeneca and Boehringer Ingelheim, grant support, and lecture fees, paid to his institution, from Pfizer, Biotronic, Edwards Lifesciences, Bayer HealthCare, and GlaxoSmithKline, grant support from Medtronic, Abbott Vascular, and Boston Scientific, and consulting fees, paid to his institution, from the Medicines Company; Dr. Bernlochner, receiving grant support from MSD Sharp & Dohme and lecture fees from Sysmex Europe; Dr. Landmesser, receiving lecture fees and advisory fees from AstraZeneca, Amgen, Sanofi, Berlin Chemie, and Abbott, advisory fees from the Medicines Company, and grant support, lecture fees, and advisory fees from Bayer; Dr. Katus, receiving consulting fees from Bayer Vital, Novo Nordisk, AstraZeneca, and Daiichi Sankyo and lecture fees from Boehringer Ingelheim; Dr. Sibbing, receiving lecture fees and advisory board fees from Bayer, Sanofi Aventis, AstraZeneca, and Daiichi Sankyo, lecture fees from Pfizer, grant support and lecture fees from Roche Diagnostics, and advisory board fees from Ferrer; Dr. Möllmann, receiving lecture fees from AstraZeneca, Bayer, Boehringer Ingelheim, Bristol-Myers Squibb, Daiichi Sankyo, and Pfizer; Dr. Hochholzer, receiving lecture fees from AstraZeneca, Bayer Vital, Bristol-Myers Squibb, and Boehringer Ingelheim, lecture fees and consulting fees from Daiichi Sankyo, and consulting fees from the Medicines Company; Dr. Schühlen, receiving grant support, paid to his institution, and consulting fees from AstraZeneca and grant support, paid to his institution, and lecture fees from Daiichi Sankyo; Dr. Angiolillo, receiving grant support, consulting fees, and honoraria from Amgen, Aralez, Bayer, Biosensors, Boehringer Ingelheim, Bristol-Myers Squibb, Chiesi, Daiichi Sankyo, Eli Lilly, Janssen, Merck, Sanofi, and AstraZeneca, consulting fees and honoraria from Haemonetics, PhaseBio, PLx Pharma, Pfizer, and the Medicines Company, grant support and fees for review activities from CeloNova, fees for review activities from St. Jude Medical, and grant support from CSL Behring, Eisai, Gilead, Idorsia Pharmaceuticals, Matsutani Chemical Industry, Novartis, Osprey Medical, and RenalGuard Solutions; Dr. Hamm, receiving advisory board fees and lecture fees from AstraZeneca; Dr. Trenk, receiving lecture fees from Amgen, AstraZeneca, Berlin Chemie, Bristol-Myers Squibb, Pfizer, and Sanofi, lecture fees and fees for serving on a speakers’ bureau from Bayer, Boehringer Ingelheim, and Daiichi Sankyo; and Dr. Schunkert, receiving honoraria from MSD Sharp & Dohme, Amgen, Bayer Vital, Boehringer Ingelheim, Daiichi Sankyo, Novartis, Servier, Brahms, Bristol-Myers Squibb, Medtronic, Sanofi-Aventis, and Synlab and grant support, paid to his institution, from AstraZeneca. No other potential conflict of interest relevant to this article was reported.

This article was published on September 1, 2019, at NEJM.org.

A data sharing statement provided by the authors is available with the full text of this article at NEJM.org.


Source link
Tags
Show More

Leave a Reply

Back to top button
Close
Skip to toolbar